Randstad Sourceright Releases Report on Demand for Key Jobs in the US During COVID-19
This week, Randstad Sourceright released its report, “How is Key Talent in the US Impacted by COVID-19?” The report analyzes data from the Bureau of Labor Statistics, World Health Organization, job boards, career sites, and social media postings to map the demand for key jobs in the US.
The report identifies the changes in demand for key jobs across six job families between January 2019 and April 2020, one of which is chemistry (pharmaceutical R&D).
While there has been a 17% decrease in overall pharma R&D jobs from February to March, the demand for clinical research associates and trial managers has increased by 46%, making it one of the few industries that has had to increase hiring since the start of the pandemic. These were identified as the two most sought after roles in pharma R&D. It is projected that the pandemic will accelerate the shortage of talent and increase recruitment activities for these roles.
The report aims to identify the shift in demand for certain skills, which will inform employers on how to be more prepared to recruit and hire once things return to normal.
For more information, click here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
